Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.

Cardiovascular diabetology - 14 May 2026

Chen Zekai, Triatin Rima D, Luo Li, Snieder Harold, Schmidt A Floriaan, Ditmarsch Marc, Kastelein John J P, Dullaart Robin P F, Kuivenhoven Jan Albert, Thio Chris H L

Abstract excerpt

BACKGROUND AND AIMS: Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) is the cornerstone in the prevention of coronary artery disease (CAD) but may also increase risk of type 2 diabetes (T2D). A comprehensive examination of the genetic evidence of T2D related side-effects of all current lipid-modifying drugs, including those in development, has not yet been performed. METHODS: This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Hypolipidemic Agents

Share to Lipids

Share to Mendelian Randomization Analysis

Share to Molecular Targeted Therapy

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 42135799
DOI: 10.1186/s12933-026-03209-w
PMCID: PMC13344049

Genes

CAD
ACLY
ANGPTL3
ANGPTL4
APOB
APOC3
CETP
HMGCR
LDLR
LIPG
LPA
MTTP
NPC1L1
PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.PMID 42135799Read ↗

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read ↗

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read ↗

Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.Semantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.Semantic proximity Read ↗

Genetic association of lipids and lipid-lowering drug targets with the risk of type 1 diabetes and its complicationsSemantic proximity Read ↗

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.Semantic proximity Read ↗

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity Read ↗

Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study.Semantic proximity Read ↗

Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations.Semantic proximity Read ↗

Genetic Association between Lipid-Regulating Drug Targets and Diabetic Retinopathy: A Drug Target Mendelian Randomization StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.